January 20, 2023 07:37 AM ESTUpdated 08:46 AM

As monotherapy data disappoint, Cyteir lets go of 35 staffers, goes all in on ovarian cancer

Amber Tong

Over the summer, as the biotech blues dragged on and depressed Cyteir Therapeutics shares, execs decided to postpone clinical plans for a second candidate and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As monotherapy data disappoint, Cyteir lets go of 35 staffers, goes all in on ovarian cancer

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

As monother­a­py da­ta dis­ap­point, Cyteir lets go of 35 staffers, goes all in on ovar­i­an can­cer

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

As monotherapy data disappoint, Cyteir lets go of 35 staffers, goes all in on ovarian cancer

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved